From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib

Sunitinib, a multityrosine kinase inhibitor, is currently the standard first-line therapy in metastatic renal cell carcinoma (mRCC) and is also used in treating patients with pancreatic neuroendocrine and imatinib-resistant gastrointestinal stromal tumors (GIST). Nevertheless, most patients eventual...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Aziz, Amal Kamal, Abdel-Naim, Ashraf B., Shouman, Samia, Minucci, Saverio, Elgendy, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641351/
https://www.ncbi.nlm.nih.gov/pubmed/29066973
http://dx.doi.org/10.3389/fphar.2017.00718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641351/
https://www.ncbi.nlm.nih.gov/pubmed/29066973
http://dx.doi.org/10.3389/fphar.2017.00718

Ejemplares similares